Compare ARK Genomic Revolution ETF (ARKG) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Expedia Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.5, while Expedia Group Inc trades at $329 (market cap $39.07B). The key difference: Expedia Group Inc pays a 0.59% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | EXPE | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.69 | $325.57 |
52-Week Low | $24.02 | $188.51 |
Market Cap | — | $39.07B |
Enterprise Value | — | $37.63B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Genomic Revolution ETF (ARKG) trades at $44.69, up 0.31% with a bullish technical signal from moving averages but bearish oscillators. The ETF focuses on small- and mid-cap biotech stocks with 59% concentration in top 10 holdings. Recent news highlights ARKG's recovery from a 15% July correction, with biotech sector strength driven by FDA developments and M&A activity.
ARKG offers exposure to genomic innovation with improving valuations but faces sector volatility risks. The ETF's long-term EPS growth rate of 10.7% supports growth potential, though concentrated holdings and technical overbought signals warrant caution amid broader market sensitivity.
Expedia Group (EXPE) trades at $328.31, up 2.25% today, with a bullish technical signal and strong earnings momentum after Q2 2026 EPS of $5.76 beat estimates. The stock shows robust fundamentals with a 90.43% gross margin and 12.97% net margin, supported by positive cash flow trends and raised full-year revenue guidance. Recent news highlights AI and B2B growth driving optimism.
Outlook remains positive with analyst consensus leaning buy, though high RSI indicates overbought conditions. Key risks include travel demand sensitivity and competitive pressures, but solid earnings beats and institutional support suggest continued upside potential near the $330 resistance level.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
